NCT06293950RecruitingPhase 1
Allogeneic Wharton Jelly Mesenchymal Stromal Cell (WJMSC) for Treatment of Autism
Source: ClinicalTrials.gov · Last updated 24 Jan 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Autism spectrum disorders (ASDs) are characterized by core domains: persistent deficits in social communication and interaction; restricted, repetitive patterns of behavior, interests, or activities.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (estimated)
- First submitted
- 9 May 2023
- Start date
- 9 Mar 2022
- Primary completion date
- Jun 2026
- Lead sponsor
- University of Jordan
- Diseases
- Autism
- NCT number
- NCT06293950
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 14
- From 9 Mar 2022 to the primary completion date, Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of any stimulant or non-stimulant medication or medications given for attention deficit hyperactivity disorder (ADHD) must be discontinued 7 days before the initial randomized study period.
- Subjects taking a selective serotonin reuptake inhibitor (SSRI) must be on a stable dose for a minimum of 30 days before entering the study.
- Prior history of stroke in utero or other in utero insult.
Other illness
- History of severe Allergy
- History of severe head trauma, defined by loss of consciousness or hospitalization, skull fracture, or stroke.
- Seizure within the last year before enrollment, or the need for seizure medications either at present or in the past.
- Evidence or history of severe, moderate, or uncontrolled systemic disease.
- History of premature birth \<35 weeks' gestation.
Age
- Age \> 14 years.
Other
- Patient weighing \< 10 kg.
- Inability to follow the prescribed dosing and follow-up schedule.
Who the study is looking for
- 14 subjects, 4-14 years of age, will be enrolled into this study, who meet the criteria for (ASD
Age in the registry: 4 years to 14 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cell Therapy Center Coordinator of this site? Confirm its status | Amman | Jordan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.